Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients.

Espinoza-Sánchez NA, Győrffy B, Fuentes-Pananá EM, Götte M.

J Cancer. 2019 Aug 28;10(21):5191-5211. doi: 10.7150/jca.34302. eCollection 2019.

2.

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.

Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Győrffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD.

Elife. 2019 Sep 3;8. pii: e47327. doi: 10.7554/eLife.47327.

3.

Evidence for the Oocyte Mosaicism Selection model on the origin of Patau syndrome (trisomy 13).

Babay LÉ, Horányi D, Győrffy B, Nagy GR.

Acta Obstet Gynecol Scand. 2019 Aug 29. doi: 10.1111/aogs.13694. [Epub ahead of print]

PMID:
31464342
4.

Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer.

Perone Y, Farrugia AJ, Rodríguez-Meira A, Győrffy B, Ion C, Uggetti A, Chronopoulos A, Marrazzo P, Faronato M, Shousha S, Davies C, Steel JH, Patel N, Del Rio Hernandez A, Coombes C, Pruneri G, Lim A, Calvo F, Magnani L.

Nat Commun. 2019 Aug 19;10(1):3791. doi: 10.1038/s41467-019-11801-w.

5.

JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.

Mohrherr J, Haber M, Breitenecker K, Aigner P, Moritsch S, Voronin V, Eferl R, Moriggl R, Stoiber D, Győrffy B, Brcic L, László V, Döme B, Moldvay J, Dezső K, Bilban M, Popper H, Moll HP, Casanova E.

Int J Cancer. 2019 Aug 12. doi: 10.1002/ijc.32624. [Epub ahead of print]

PMID:
31407334
6.

Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion.

Nguyen VTM, Barozzi I, Faronato M, Lombardo Y, Steel JH, Patel N, Darbre P, Castellano L, Győrffy B, Woodley L, Rodriguez-Meira A, Patten DK, Vircillo V, Periyasamy M, Ali S, Frige G, Minucci S, Coombes RC, Magnani L.

Nat Commun. 2019 Aug 6;10(1):3505. doi: 10.1038/s41467-019-11569-z.

7.

Identifying Cancers Impacted by CDK8/19.

Roninson IB, Győrffy B, Mack ZT, Shtil AA, Shtutman MS, Chen M, Broude EV.

Cells. 2019 Aug 3;8(8). pii: E821. doi: 10.3390/cells8080821.

8.

Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer.

Schölch S, Bogner A, Bork U, Rahbari M, Győrffy B, Schneider M, Reissfelder C, Weitz J, Rahbari NN.

Sci Rep. 2019 Jul 29;9(1):10921. doi: 10.1038/s41598-019-47429-5.

9.

Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes.

Menyhart O, Kakisaka T, Pongor LS, Uetake H, Goel A, Győrffy B.

Cancers (Basel). 2019 Jul 14;11(7). pii: E983. doi: 10.3390/cancers11070983.

10.

Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival.

Nagy Á, Ősz Á, Budczies J, Krizsán S, Szombath G, Demeter J, Bödör C, Győrffy B.

J Adv Res. 2019 Jun 11;20:105-116. doi: 10.1016/j.jare.2019.05.006. eCollection 2019 Nov.

11.

Prognostic value of DLGAP5 in colorectal cancer.

Branchi V, García SA, Radhakrishnan P, Győrffy B, Hissa B, Schneider M, Reißfelder C, Schölch S.

Int J Colorectal Dis. 2019 Aug;34(8):1455-1465. doi: 10.1007/s00384-019-03339-6. Epub 2019 Jul 8.

PMID:
31286215
12.

GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer.

Sawada Y, Kikugawa T, Iio H, Sakakibara I, Yoshida S, Ikedo A, Yanagihara Y, Saeki N, Győrffy B, Kishida T, Okubo Y, Nakamura Y, Miyagi Y, Saika T, Imai Y.

Int J Cancer. 2019 Jul 5. doi: 10.1002/ijc.32554. [Epub ahead of print]

PMID:
31276604
13.

STAT3β is a tumor suppressor in acute myeloid leukemia.

Aigner P, Mizutani T, Horvath J, Eder T, Heber S, Lind K, Just V, Moll HP, Yeroslaviz A, Fischer MJM, Kenner L, Győrffy B, Sill H, Grebien F, Moriggl R, Casanova E, Stoiber D.

Blood Adv. 2019 Jul 9;3(13):1989-2002. doi: 10.1182/bloodadvances.2018026385.

14.

Low level of exosomal long non-coding RNA HOTTIP is a prognostic biomarker in colorectal cancer.

Oehme F, Krahl S, Gyorffy B, Muessle B, Rao V, Greif H, Ziegler N, Lin K, Thepkaysone ML, Polster H, Tonn T, Schneider M, Weitz J, Baenke F, Kahlert C.

RNA Biol. 2019 Oct;16(10):1339-1345. doi: 10.1080/15476286.2019.1637697. Epub 2019 Jul 7. Erratum in: RNA Biol. 2019 Oct 3;:1.

PMID:
31251124
15.

Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan.

Menyhárt O, Fekete JT, Győrffy B.

Int J Mol Sci. 2019 Jun 5;20(11). pii: E2750. doi: 10.3390/ijms20112750.

16.

Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.

Menyhárt O, Győrffy B.

Ann Clin Transl Neurol. 2019 Mar 19;6(5):990-1005. doi: 10.1002/acn3.762. eCollection 2019 May. Review.

17.

Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.

Sávolt Á, Cserni G, Lázár G, Maráz R, Kelemen P, Kovács E, Győrffy B, Udvarhelyi N, Vörös A, Ormándi K, Mátrai Z.

Eur J Surg Oncol. 2019 Oct;45(10):1835-1838. doi: 10.1016/j.ejso.2019.05.016. Epub 2019 May 16.

PMID:
31126680
18.

BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.

Shafran JS, Andrieu GP, Györffy B, Denis GV.

Mol Cancer Res. 2019 Aug;17(8):1627-1638. doi: 10.1158/1541-7786.MCR-18-1279. Epub 2019 May 20.

PMID:
31110158
19.

SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer.

Perone Y, Farrugia AJ, Rodríguez-Meira A, Győrffy B, Ion C, Uggetti A, Chronopoulos A, Marrazzo P, Faronato M, Shousha S, Davies C, Steel JH, Patel N, Del Rio Hernandez A, Coombes C, Pruneri G, Lim A, Calvo F, Magnani L.

Nat Commun. 2019 May 9;10(1):2115. doi: 10.1038/s41467-019-09676-y. Erratum in: Nat Commun. 2019 Aug 19;10(1):3791.

20.

ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients.

Fekete JT, Győrffy B.

Int J Cancer. 2019 Dec 1;145(11):3140-3151. doi: 10.1002/ijc.32369. Epub 2019 May 7.

PMID:
31020993
21.

Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2.

Cherfils-Vicini J, Iltis C, Cervera L, Pisano S, Croce O, Sadouni N, Győrffy B, Collet R, Renault VM, Rey-Millet M, Leonetti C, Zizza P, Allain F, Ghiringhelli F, Soubeiran N, Shkreli M, Vivier E, Biroccio A, Gilson E.

EMBO J. 2019 Jun 3;38(11). pii: e100012. doi: 10.15252/embj.2018100012. Epub 2019 Apr 18.

PMID:
31000523
22.

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.

Morcillo-Garcia S, Noblejas-Lopez MDM, Nieto-Jimenez C, Perez-Peña J, Nuncia-Cantarero M, Győrffy B, Amir E, Pandiella A, Galan-Moya EM, Ocana A.

PLoS One. 2019 Apr 16;14(4):e0209134. doi: 10.1371/journal.pone.0209134. eCollection 2019.

23.

Mapping Bromodomains in breast cancer and association with clinical outcome.

Pérez-Pena J, Páez R, Nieto-Jiménez C, Sánchez VC, Galan-Moya EM, Pandiella A, Győrffy B, Ocana A.

Sci Rep. 2019 Apr 5;9(1):5734. doi: 10.1038/s41598-019-41934-3.

24.

Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.

Menyhárt O, Giangaspero F, Győrffy B.

J Hematol Oncol. 2019 Mar 15;12(1):29. doi: 10.1186/s13045-019-0712-y. Review.

25.

BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress.

Fernando TM, Marullo R, Pera Gresely B, Phillip JM, Yang SN, Lundell-Smith G, Torregroza I, Ahn H, Evans T, Győrffy B, Privé GG, Hirano M, Melnick AM, Cerchietti L.

Cancer Discov. 2019 May;9(5):662-679. doi: 10.1158/2159-8290.CD-17-1444. Epub 2019 Feb 18.

PMID:
30777872
26.

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer.

Vendrell JA, Solassol J, Győrffy B, Vilquin P, Jarlier M, Donini CF, Gamba L, Maudelonde T, Rouanet P, Cohen PA.

Front Pharmacol. 2019 Jan 25;9:1581. doi: 10.3389/fphar.2018.01581. eCollection 2018.

27.

Correction: Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.

Kang MH, Jeong KJ, Kim WY, Lee HJ, Gong G, Suh N, Győrffy B, Kim S, Jeong SY, Mills GB, Park YY.

Oncogene. 2019 May;38(22):4427-4428. doi: 10.1038/s41388-019-0721-x.

PMID:
30718918
28.

Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells.

Muniraj N, Siddharth S, Nagalingam A, Walker A, Woo J, Gyorffy B, Gabrielson E, Saxena NK, Sharma D.

Carcinogenesis. 2019 Jan 29. doi: 10.1093/carcin/bgz015. [Epub ahead of print]

PMID:
30698683
29.

Independent validation of induced overexpression efficiency across 242 experiments shows a success rate of 39.

Munkácsy G, Herman P, Győrffy B.

Sci Rep. 2019 Jan 23;9(1):343. doi: 10.1038/s41598-018-36122-8.

30.

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer.

Menyhárt O, Pongor LS, Győrffy B.

Front Pharmacol. 2019 Jan 8;9:1522. doi: 10.3389/fphar.2018.01522. eCollection 2018.

31.

Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma.

Menyhárt O, Nagy Á, Győrffy B.

R Soc Open Sci. 2018 Dec 5;5(12):181006. doi: 10.1098/rsos.181006. eCollection 2018 Dec.

32.

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Budczies J, Seidel A, Christopoulos P, Endris V, Kloor M, Győrffy B, Seliger B, Schirmacher P, Stenzinger A, Denkert C.

Oncoimmunology. 2018 Oct 19;7(12):e1526613. doi: 10.1080/2162402X.2018.1526613. eCollection 2018.

33.

Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.

Merino VF, Cho S, Nguyen N, Sadik H, Narayan A, Talbot C Jr, Cope L, Zhou XC, Zhang Z, Győrffy B, Sukumar S.

Breast Cancer Res. 2018 Nov 28;20(1):145. doi: 10.1186/s13058-018-1068-x.

34.

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene.

Noblejas-López MDM, Morcillo-García S, Nieto-Jiménez C, Nuncia-Cantarero M, Győrffy B, Galan-Moya EM, Pandiella A, Ocaña A.

PLoS One. 2018 Nov 28;13(11):e0207776. doi: 10.1371/journal.pone.0207776. eCollection 2018.

35.

EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.

Atkinson CJ, Kawamata F, Liu C, Ham S, Győrffy B, Munn AL, Wei MQ, Möller A, Whitehall V, Wiegmans AP.

Mol Oncol. 2019 Apr;13(4):725-737. doi: 10.1002/1878-0261.12411. Epub 2019 Feb 8.

36.

Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.

Chernikova SB, Nguyen RB, Truong JT, Mello SS, Stafford JH, Hay MP, Olson A, Solow-Cordero DE, Wood DJ, Henry S, von Eyben R, Deng L, Gephart MH, Aroumougame A, Wiese C, Game JC, Győrffy B, Brown JM.

J Clin Invest. 2018 Dec 3;128(12):5307-5321. doi: 10.1172/JCI87191. Epub 2018 Oct 29.

37.

Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment.

Marcell Szasz A, Malm J, Rezeli M, Sugihara Y, Betancourt LH, Rivas D, Gyorffy B, Marko-Varga G.

Cell Biol Toxicol. 2019 Feb;35(1):1-14. doi: 10.1007/s10565-018-9446-9. Epub 2018 Oct 24. Review.

38.

A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy.

Gelfo V, Mazzeschi M, Grilli G, Lindzen M, Santi S, D'Uva G, Győrffy B, Ardizzoni A, Yarden Y, Lauriola M.

Cancers (Basel). 2018 Sep 26;10(10). pii: E355. doi: 10.3390/cancers10100355.

39.

The phosphatidic acid phosphatase lipin-1 facilitates inflammation-driven colon carcinogenesis.

Meana C, García-Rostán G, Peña L, Lordén G, Cubero Á, Orduña A, Győrffy B, Balsinde J, Balboa MA.

JCI Insight. 2018 Sep 20;3(18). pii: 97506. doi: 10.1172/jci.insight.97506. eCollection 2018 Sep 20.

40.

Factors influencing the scientific performance of Momentum grant holders: an evaluation of the first 117 research groups.

Győrffy B, Nagy AM, Herman P, Török Á.

Scientometrics. 2018;117(1):409-426. doi: 10.1007/s11192-018-2852-1. Epub 2018 Jul 20.

41.

Demographic shift disproportionately increases cancer burden in an aging nation: current and expected incidence and mortality in Hungary up to 2030.

Menyhárt O, Fekete JT, Győrffy B.

Clin Epidemiol. 2018 Aug 29;10:1093-1108. doi: 10.2147/CLEP.S155063. eCollection 2018.

42.

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A.

Breast Cancer Res Treat. 2018 Dec;172(3):725-732. doi: 10.1007/s10549-018-4965-x. Epub 2018 Sep 11.

PMID:
30206781
43.

Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts.

Barone I, Vircillo V, Giordano C, Gelsomino L, Győrffy B, Tarallo R, Rinaldi A, Bruno G, Caruso A, Romeo F, Bonofiglio D, Andò S, Catalano S.

Cancer Lett. 2018 Nov 28;437:89-99. doi: 10.1016/j.canlet.2018.08.026. Epub 2018 Sep 1.

PMID:
30176263
44.

Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.

Than NG, Romero R, Tarca AL, Kekesi KA, Xu Y, Xu Z, Juhasz K, Bhatti G, Leavitt RJ, Gelencser Z, Palhalmi J, Chung TH, Gyorffy BA, Orosz L, Demeter A, Szecsi A, Hunyadi-Gulyas E, Darula Z, Simor A, Eder K, Szabo S, Topping V, El-Azzamy H, LaJeunesse C, Balogh A, Szalai G, Land S, Torok O, Dong Z, Kovalszky I, Falus A, Meiri H, Draghici S, Hassan SS, Chaiworapongsa T, Krispin M, Knöfler M, Erez O, Burton GJ, Kim CJ, Juhasz G, Papp Z.

Front Immunol. 2018 Aug 8;9:1661. doi: 10.3389/fimmu.2018.01661. eCollection 2018.

45.

Tip110/SART3 regulates IL-8 expression and predicts the clinical outcomes in melanoma.

Timani KA, Győrffy B, Liu Y, Mohammad KS, He JJ.

Mol Cancer. 2018 Aug 17;17(1):124. doi: 10.1186/s12943-018-0868-z.

46.

Author Correction: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets.

Nagy Á, Lánczky A, Menyhárt O, Győrffy B.

Sci Rep. 2018 Jul 26;8(1):11515. doi: 10.1038/s41598-018-29514-3.

47.

Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.

Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L.

Nat Med. 2018 Sep;24(9):1469-1480. doi: 10.1038/s41591-018-0091-x. Epub 2018 Jul 23.

48.

[Genome engineering using the CRISPR-Cas9 system and applications in cancer research].

Hudacsek V, Gyõrffy B.

Magy Onkol. 2018 Jul 20;62(2):119-127. Epub 2018 Jan 6. Hungarian.

49.

[Longer oral contraception history as a possible preventive factor against fetal trisomy 21 in advanced maternal age pregnancies].

Horányi D, Babay LÉ, Győrffy B, Nagy GR.

Orv Hetil. 2018 Jul;159(28):1146-1152. doi: 10.1556/650.2018.31094. Hungarian.

PMID:
29983104
50.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635

Supplemental Content

Loading ...
Support Center